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The amyloid precursor protein (APP) interacts with the tropomyosin receptor kinase A
(TrkA) in normal rat, mouse, and human brain tissue but not in Alzheimer’s disease
(AD) brain tissue. However, it has not been reported whether the two proteins
interact directly, and if so, which domains are involved. Clarifying these points will
increase our understanding of the role and regulation of the TrkA/APP interaction
in normal brain functioning as well as in AD. Here we addressed these questions
using bimolecular fluorescence complementation (BiFC) and the proximity ligation assay
(PLA). We demonstrated that exogenously expressed APP and TrkA associate through
their juxtamembrane/transmembrane domains, to form a complex that localizes mainly
to the plasma membrane, endoplasmic reticulum (ER) and Golgi. Formation of the
complex was inhibited by p75NTR, ShcC and Mint-2. Importantly, we demonstrated
that the association between endogenous APP and TrkA in primary septal neurons
were modified by NGF, or by drugs that either inhibit ER-to-Golgi transport or perturb
microtubules and microfilaments. Interestingly, several agents that induce cell death
[amyloid β (Aβ)-peptide, staurosporine and rapamycin], albeit via different mechanisms,
all caused dissociation of APP/TrkA complexes and increased production of C-terminal
fragment (β-CTF) APP fragment. These findings open new perspectives for investigating
the interplay between these proteins during neurodegeneration and AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disease that causes progressive decline of
cognitive function in elderly people. The neuropathology of AD is marked by formation
of extracellular amyloid-beta (Aβ) peptide plaques and intracellular neurofibrillary tangles
(NFT), along with synapse and cell loss in selected brain areas including the cholinergic basal
forebrain neurons (CBFN) (Zaboroszky et al., 2012). Impaired cholinergic neurotransmission
has been proposed as potentially causal for the formation of plaques and tangles; these, in
turn, exacerbate the cholinergic deficit (Kar et al., 2004; Adalbert et al., 2007; Belarbi et al.,
2009; Vana et al., 2011). The viability of CBFN depends on nerve growth factor (NGF),
which is produced by CBFN targets. Once bound and internalized, NGF is transported in a
retrograde fashion to the cell body through interaction with the high-affinity TrkA and the low-
affinity (p75NTR) neurotrophin receptors. Accumulating evidence highlights connections between
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the trafficking and signaling of NGF receptors with the processing
and signaling of APP. Thus, perturbations in the expression or
retrograde transport of NGF, TrkA or p75NTR can underlie
CBFN dysfunction and altered APP and tau processing in AD
(Capsoni et al., 2002; Isacson et al., 2002).
p75NTR, which is highly expressed in adult CBFN neurons,
induces apoptosis in the absence of NGF (Casaccia-Bonnefil
et al., 1996; Frade et al., 1996). The receptor also binds directly
to Aβ-peptide, thereby enhancing peptide toxicity (Rabizadeh
et al., 1994; Yaar et al., 1997). Moreover, p75NTR binds directly
to APP. This interaction, which is inhibited by NGF and by
Aβ-peptide, results in altered APP processing and reduced
APP-mediated transcriptional activity (Fombonne et al., 2009).
Interplay between TrkA and APP has also been reported.
Decreased binding of NGF to TrkA leads to increased production
of Aβ-peptide and to apoptotic death (Matrone et al., 2011; Triaca
et al., 2016). TrkA interacts with APP (Matrone et al., 2011;
Zhang et al., 2014). This depends on APP phosphorylation at
Y682 (Tarr et al., 2002a; Matrone et al., 2011) and has been
correlated with APP-processing (Tarr et al., 2002a; Barbagallo
et al., 2010; Zhang et al., 2014), APP-mediated transcriptional
activity, and cell death (Zhang et al., 2014). In turn, APP regulates
the NGF/TrkA signaling pathway (Matrone et al., 2011), the
sub-cellular distribution of TrkA (Matrone et al., 2011; Zhang
et al., 2014), the endocytosis of the TrkA/p75NTR/NGF complex
(Zhang et al., 2013), and the sensitivity of neurons to the trophic
action of NGF (Matrone et al., 2011).
In consideration of these phenomena, NGF therapy has been
proposed as an approach to counteract CBFN degeneration in
AD patients (Williams et al., 2006).
Amyloid precursor protein and p75NTR interact directly
(Zhang et al., 2013), but it is not known whether the same
is true for APP and TrkA. In the present work, we used co-
immunoprecipitation of selected TrkA and APP deletion mutants
in transfected HEK293 cells to map interacting domains. Next,
we used BiFC and PLA assays, two techniques that can identify
interacting proteins, i.e., spaced within 7 and 15nm, respectively.
BiFC is based on assembling a functional yellow fluorescent
protein (YFP), by expressing two halves of YFP as fusions with
cellular proteins that themselves interact. The interaction can
then be detected by fluorescent microscopy and quantified by
flow cytometry (FC) (Morell et al., 2008). In situ PLA uses
antibody-coupled oligonucleotides together with DNA ligation
and polymerization as a means to detect interaction between
proteins of interest (Greenwood et al., 2015). PLA visualizes and
quantifies contacts between specific proteins, in their normal
context and at physiological expression levels, with extreme
specificity. Moreover, PLA allows detection of single event with
subcellular resolution, and generation of cell-to-cell statistics.
Using these approaches, we found that for APP and TrkA
association their juxtamembrane and TMD domains respectively
are sufficient. This interaction does not require tyrosine-
phosphorylation of TrkA and is inhibited by p75NTR, ShcC
and Mint-2. APP/TrkA complexes localize to the ER, Golgi,
and plasma membrane. Formation of APP/TrkA complexes is
promoted by NGF and is conversely reduced by agents that
disrupt intracellular protein traffic, Aβ-peptide, and inducers of
cell death. Interestingly, the loss of APP/TrkA complexes occurs
rapidly, preceding the loss of cell viability.
MATERIALS AND METHODS
Rodent NGF was from Xiamen, Bioway.
Antibodies
Antibodies used in this study were: mouse APP 22C11 (MAB348,
Millipore), mouse APP-CT (clone C1/6.1 802801, Biolegend),
rabbit APP-CT (A8717, Sigma Aldrich), rabbit APP-NT (A8967
Sigma Aldrich), rabbit monoclonal TrkA [EP1058Y] (Abcam,
ab76291), mouse and rabbit pan-Trk (sc-7268 and sc-11,
respectively), rabbit TrkA NT H-190 (sc-14024), rabbit TrkB
(794) (Sc-12) and TrkC (Sc-117), goat polyclonal Calnexin (Sc-
6465) and GM130 (Sc-16270), and mouse Bcl2 (sc-7382) were
from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Goat
Anti-Choline Acetyltransferase (ChAT) antibody (AB144P) was
from Millipore. Rabbit cleaved/caspase-3 (Asp175) (#9661) was
from Cell Signaling
Plasmid Vectors
pAPP-695 (1–695); pAPP-1-CT (1–651); pAPP-s-α (1–612),
pAPP-C99 (597–695), and pAPP Sw/Ind (Swedish and Indiana
mutation) plasmids were gently provided by Dr. Dennis Selkoe
(Addgene: plasmids: #30137; 30143; #30147; #30146; #30145).
pAPP-Y682G plasmid harboring mutation on the tyrosine 682
residue to glycine was obtained by site directed mutagenesis
(Q5 R© Site-Directed Mutagenesis Kit, New England Biolabs,
E0554S). pAPP-C83 (613-695) plasmid was obtained by
polymerase chain reaction (PCR) using pAPP-695 as PCR
template.
pTrkA, pTrkA-1-CT, and pTrkA-1-NT plasmids were
constructed starting from the DM38 vector coding for the human
TrkA cDNA generously provided by Dr. Mariano Barbcid.
Briefly, the Eco-RI fragment of TrkA cDNA was excited from
DM38 vector, cloned in Eco-RI site of pBlue-script KS+ vector
and then in pCDNA-3 vector as Hind-III-Xba-I fragment, to
obtain pTrkA vector (1–799) coding for TrkA full length. pTrkA-
1N-CT (1–488) vector was obtained inserting a stop codon into
BspHI restriction site (1403 nt) of TrkA cDNA. pTrkA-1-NT
(354–799) vector was obtained cloning the HindII-EcoRI TrkA
fragment in frame and downstream the Ig leader sequence in
pCDNA-3 vector. pCMV5-TrkA (K538A) was kindly provided
by Dr. Moses Chao. TrkA-YFP plasmid was gently provided by
Dr. Simon Alegoua and Dr. Annette Dolphin. APP-CFP plasmid
was gently provided by Dr. Carmela Abraham. pCMV5-p75NTR
plasmid was gently provided by Dr. Corinna Giorgi.
pTrkA-VN, pTrkA-VC, pErbB3-VN were described
previously (Shen and Maruyama, 2011). For generation of
pAPP-695-VN (APP-VN), pAPP-Sw/Ind-VN and pAPP-
Y682G-VN vectors, the SacI-EcoRI fragment containing
the FLAG tag sequence was removed from the vector
pBiFC-VN173, to prevent the tag fusions with APP, and
substituted with a new SacI-EcoRI fragment [lacking Flag,
HindIII, NotI and EagI DNA sequences and formed by
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annealed complementary pair of oligonucleotides designed to
harbor SacI and EcoRI sites], to obtain the pBiFC-D-Flag-VN
vector.
Primer forward: 5′-cgtttagtgaaccgtcagaattgtctg-3′ and
Primer reverse: 5′-aattcagacaattctgacggttcactaaacgagct -3′
PCR products encoding human APP-695, APP-Sw/Ind and
APP-Y682G proteins were amplified using pAPP-695, pAPP-
Sw/Ind and pAPP-Y682G plasmids as PCR template using the
following primer pairs:
Primer forward: 5′-gatatcatgctgcccggtttggcactgctcctgctg-3′
containing the EcoRV restriction and Kozak sequences
Primer reverse: 5′-gctctagacgtagcaaccggcgggtccctagccctcggaacc
gtggagttctgcatctgctcaaagaactt-3′, containing sequences coding
for linker STVPRARDPPVAT and Xba-I site for cloning APP in
frame with VN in pBiFC-1-Flag-VN vector.
APP-C99-VN and APP-C83-VN vectors were generated after
cloning C99 and C83 downstream and in frame with the signal
peptide of APP in pCDNA3. From this vector both fused
fragments were excised as EcoRI and XbaI fragment and cloned
in pBiFC-VN vector. APP-1-CT-VN and APP-s-α-VN vectors
were amplified by PCR and cloned in pBiFC-VN.
To generate TrkA-1-CT-VC vector, the fragment (residues
1–488) was amplified and cloned into EcoRI-Xho sites of
BiFC vector. To generate TrkA-1-CT-VC vector, the fragment
354–799 was amplified and cloned downstream and in frame
with the signal peptide of TrkA (residues 1–36) in pCDNA-
3. The EcoRI-XhoI fragment was then excised and cloned in
pBiFC-VC vector. To generate TrkA 354-488-VC vector, the
TrkA sequence between residues 354 and 488, comprising the
transmembrane domain, was cloned downstream and in frame
with the signal peptide of TrkA in pCDNA-3, excised as EcoRI-
XhoI fragment and cloned in BiFC-VC vector. The validity of the
constructs were confirmed by DNA sequencing and WB analysis.
Mint-2 plasmid was gently provided by Dr. Thomas C. Südhof.
Plasmid for ShcC was from Origene (SC114141). DsRed-Rab-5
and DsRed-Rab11 plasmids were gently provided by Dr. Pagano
(Addgene plasmids #13050, #12679 respectively). tdTomato-
MannII-N-10 and mCherry-ER-3 plasmids were gently provided
by Dr. Davidson (Addgene plasmids: #58110 and #55041
respectively).
Cell Cultures
Septal neurons were prepared from embryonic day 17/18
(E17/18) pregnant Wistar rats (Charles River) as previously
described (Triaca et al., 2016). All experiments regarding the
establishment of primary neuronal cultures from rat brain
were performed according to the national and international
laws for laboratory animal welfare and experimentation.
The experiments were performed according to a protocol
communicated to the Italian Ministry of Health on February
18 th 2014, valid until February 18th 2017, in accordance
with the guidelines and regulations of the Italian Law (DLGs
n.116, 27/1/1992). HEK293 cell line (ATCC) were cultured
in DMEM (Gibco) medium supplemented with 10% FBS
(Invitrogen), penicillin/streptomycin in 5% CO2 humidified
atmosphere, at 37◦C and transfected with Lipofectamine 2000
(Life Technologies, according to the manufacturer’s instructions).
Immunoprecipitation and Western Blot
Analysis
Cells were lysed in RIPA buffer (10 mM Tris-HCl pH
7.6, 100 mM NaCl, 10 mM EDTA, 0.5% Nonidet P40,
0.5% sodium deoxycholate) in the presence of protease and
phosphatase inhibitor cocktail (Sigma, Aldrich). Solubilized
proteins were obtained in the supernatant after centrifugation
at 13,000 rpm for 5 min. Protein concentrations were
estimated by the Bradford procedure (Bio-Rad) for all samples
except those containing SDS where the DC assay (Bio-Rad)
was used. Co-immunoprecipitations were performed on pre-
cleared solubilized proteins or supernatants using APP (22C11)
antibody, pan-Trk antibody (B3) and non-relevant monoclonal
mouse IgG antibody as control. WB were performed using
rabbit APP-CT (1:2000), APP-NT (1:2000), rabbit monoclonal
TrkA-CT (1:2000) and rabbit TrkA-NT (1:1000) antibodies.
Densitometry of the WB was analyzed with the Image J software
(NIH) and normalized to corresponding reference protein
β-actin.
Immunofluorescence
Primary septal cell cultures were fixed for 20 min in phosphate-
buffered saline (PBS) containing 4% paraformaldehyde (PFA)
and permeabilized for 5 min with 0.2% Triton X-100 at
room temperature (RT). Then, they were incubated in 0.1 M
ammonium chloride for 30 min at RT to reduce autofluorescence
and blocked with 10% normal donkey serum (NDS, Jackson
Immunoresearch) in PBS for 60 min at RT. Primary antibody
incubations were performed overnight at 4◦C. Cells were then
washed three times with PBS plus 0.1% Tween 20 at RT,
incubated with Alexa-labeled secondary antibodies (Invitrogen,
anti-mouse-546, anti-rabbit-488) for 1 h at RT in the same buffer,
counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and
mounted. Images were visualized with a confocal microscope
(TCS SP5, Leica Microsystem GmbH Wetzlar, Germany) using
a 60× 1.35 NA oil immersion objective and acquired with the
LEICA Application Suite software (Advanced Fluorescence Lite,
Leica).
For the quantitative analysis, all the images were acquired
with identical settings of brightness and contrast. The APP and
TrkA immunoreactivities were measured through densitometric
analysis by using the ImageJ software (version 1.411). Images were
converted to eight-bit images containing grayscale values from 0
(black) to 255 (white). After background subtraction, the APP
and TrkA cell-associated signals were quantified by manually
outlining individual cells. The integrated value was calculated by
summing the gray values of each pixel, and the mean intensity
value was calculated by dividing the integrated intensity by the
number of pixels.
Förster Resonance Energy Transfer
(FRET)
For standard acceptor photobleaching FRET microscopy,
HEK293 cells were seeded on coated glass coverslips and
1http://rsb.info.nih.gov/ij
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co-transfected with a vector encoding APP-CFP and a vector
encoding TrkA-YFP. Twenty-four hours after transfection,
cells were fixed with 4% paraformaldehyde for 10 min and,
following three washes, were placed on slides and embedded
in mounting medium. FRET studies were performed on a
confocal microscope (TCS SP5, Leica) using the implemented
FRET acceptor photobleaching wizard. Acquisition settings
were as follows: objective Plan-Apochromat × 63/1.4 NA oil
immersion, pinhole 2 Airy units, image size 512× 512. Prebleach
and postbleach images were serially recorded of APP-CFP
[(exicitation at 458 nm and emission at 475/500 nm (donor
channel)] and Trk-YFP [exicitation at 515 nm and emission at
530/630 (acceptor channel)]. Low laser intensities were used to
avoid bleaching effects during acquisition, selection of the cells
were made by visualizing only the donor channel to prevent
premature partial bleaching of the acceptor. The acceptor was
bleached with high intensity (100%) power at the 543 nm laser
line for 10 iterations. This iteration time was found to be effective
for bleaching TrkA-YFP in pilot experiments. The change in the
fluorescence intensity between pre- and postbleach donor values
(efficiency, E) was calculated using the formula E = (donor
after–donor before) × 100/donor after, and was shown as a
percentage. We analyzed at least10 cells from each of three
independent experiments.
Bimolecular Fluorescence
Complementation (BiFC)
Formation of complexes containing APP/TrkA ectopically
expressed in transfected HEK293 cells was measured by BiFC
(Morell et al., 2008). For confocal microscope analysis, 50,000
HEK293 cells per well were seeded on coverslips coated with
poly-L-Lysine (50 µg/ml, Sigma) and cultivated in 5% CO2 at
37◦C. On the next day, cells were co-transfected with 400 ng
of the expression vectors (200 ng each) indicated in each
experiment using Lipofectamine. The same amount of DNA
was used for each co-transfection. To evaluate the role of
p75NTR, ShcC and Mint-2 in APP/TrkA interaction, HEK293
cells, plated on 12-well plates were transfected with TrkA-
VC and APP-VN and expression vector coding for un-tagged
p75NTR, ShcC and Mint-2 at ratio of 1:1:3 respectively (200: 200:
600 ng of each plasmid). For mock, single and double plasmid
transfection, pcDNA-3 empty vector was added to standardize
the plasmid amount. 18–24 h after transfection, cells were washed
twice with PBS stained with DAPI and analyzed at confocal
microscope.
Flow Cytometry (FC)
For FC analysis, 100,000 HEK293 cells per well were seeded
in 12-well plates and cultivated in 5% CO2 at 37◦C. On the
next day, transfections with equal vector amounts (1 µg of
total amount of DNA transfected) were performed. Eighteen
to twenty-four hours after transfection, cells were washed with
PBS, trypsinized, pelleted and suspended in 1 ml PBS. The
flow cytometric analyses of the single-cell suspensions were
performed using a fluorescence-activated cell sorter (FACS;
FACScan; BD Biosciences, San Jose, CA, USA) equipped with
an argon laser emitting at 488 nm. Analysis was restricted
to live cells by gating cells that exhibited forward and side
scatter features typical of live cells. Data from the acquisition
of 20,000 cells were analyzed using CellQuest software (BD
Biosciences). Among the subsequent Histogram statistics the
“average channel number or linear value of events within a
marker” meaning the Mean statistic value, was chosen for the
following analysis.
In situ Proximity Ligation Assay (PLA)
The interaction between APP and TrkA by PLA assay
(Fredriksson et al., 2002) was detected using the corresponding
two primary antibodies raised in different species. Species-
specific secondary antibodies (PLA probes), each with a unique
short DNA strand (MINUS and PLUS) attached to it, bind to the
primary antibodies. When the PLA probes are in close proximity
the DNA strands can interact through a subsequent addition
of two other circle-forming DNA oligonucleotides. After the
amplification reaction of the DNA circle a fluorescent signal is
generated by labeled complementary oligonucleotide probes. To
perform PLA assay, primary septal cultures at 10–12 days in vitro
(DIV), treated as indicated, were immediately fixed in 4% PFA
for 15 min and thereafter subject to in situ PLA using Duolink
In Situ Detection Reagents Red kit (Sigma Aldrich, DUO92008)
according to the manufacture’s instruction. All incubations were
performed in a humidity chamber. Briefly, coverslips were
blocked with NDS for 60 min at RT and then incubated with
different anti-APP and anti-TrkA antibodies, diluted in antibody
diluent (DUO82008), overnight at 4◦C. Coverslips were washed
three times for 5 min PBS 1X and then incubated with PLA
Probe Anti-mouse MINUS (DUO92004) and Anti-rabbit PLUS
(DUO92002) for 1 h at 37◦C. Then, coverslips were washed three
times for 5 min in 1X washing buffer A (DUO82049) buffer under
gentle shaking and then incubated with a DNA ligase diluted in
Ligation buffer for 30 min at 37◦C. Coverslips were washed three
times for 2 min in 1X washing buffer A under gentle shaking and
incubated with DNA polymerase diluted in Amplification buffer
for 90 min at 37◦C. Finally, coverslips were rinsed for 10 min
in Duolink 1X washing buffer B (DUO82049) and for 2 min
in washing buffer B 0.01X. Dried coverslips were mounted with
mounting medium (DUO82040) to stain the nuclei. At the end of
this procedure, each TrkA/APP complex generated a fluorescent
red spot.
Microscope/Images Acquisition
Fluorescence images were acquired on a TCS-SP5 confocal
laser scanning microscope (Leica Mycrosystem GmbH Wetzlar,
Germany) using 63 × 1.35 NA oil immersion objective. High
resolution images were acquired as z-stack with a 0.5 µm
z-interval (at least 10 planes), and converted to maximum
projection images (to avoid subjectivity in the choice of the
plane to be analyzed) with the LASAF software platform (Leica
Microsystem) in the TIFF format.
Quantification of PLA Signal
Quantification of PLA signal was performed from at least 20
cells from different experiments as previously reported Trifilieff
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et al. (2011). High-resolution (63 × 1.35 NA) were analyzed in
ImageJ (NIH) to calculate the number of PLA puncta. Image
were first smoothed and threshold was selected manually to
discriminate PLA puncta from background fluorescence. Once
selected, this threshold was applied uniformly to all images in
the sample set. The built in macro “Analyze particle” was then
used to count all particles in the thresholded image. Objects larger
than 5 µm2 were rejected, thereby effectively removing nuclei.
The remaining objects were counted as PLA puncta. Interactions
were quantified by counting the number of dots per cell. In the
different figures, each bar (Mean ± SEM) represents the mean
obtained from the quantification of signals observed in 20–30
cells chosen randomly in five different fields from 3 independent
experiments.
Induction of Cell Death
For Aβ toxicity, primary septal cultures (10 DIV) were exposed
to 20 µm of Aβ1-40 (Abcam, Cambridge, UK). Aβ-peptide
stock solutions at a concentration of 1 mg/ml were prepared
in PBS (0.01 M NaH2PO4, 0.15 M NaCl, pH 7.4) and
stored to -20◦C. Macroautophagy was induced with rapamycin
(10 nM) a suppressor of mTOR kinase. To induce apoptosis,
neurons (10 DIV) were exposed to the protein kinase inhibitor
staurosporine (Sigma Aldrich) (30 nM). Controls were exposed
to the vehicle.
Assessment of Cell Viability
Viability was quantified by the 4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (Esposito et al., 2012)
and by counting the number of intact nuclei in a haemacytometer,
after lysing the cells in detergent-containing solution (Soto and
Sonnenschein, 1985; Volonte‘ et al., 1994; Esposito et al., 2012).
This latter method has been shown to be reproducible and
accurate and to correlate well with other methods of assessing
cell survival-death (Stefanis et al., 1997; Stefanis et al., 1999).
Briefly, the culture medium was removed and replaced with
0.5 ml of a detergent containing lysing solution (0.5% ethyl-
hexadecyldimethylammonium bromide, 0.28% acetic acid, 0.5%
Triton X-100, 3 mM NaCl, 2 mM MgCl2 in PBS pH 7.4
diluted 1/10). After 2 min, the suspension of cells was collected.
Nuclei from originally viable cells were then quantified by
counting in hemocytometer as the detergent-containing solution
selectively dissolves nuclei of dying cells. Nuclei from viable
cells thus appear as phase-bright intact circles surrounded by a
dark ring. Broken or damaged nuclei were not included in the
count.
Statistical Analysis
Values are mean ± SEM (standard error of mean) or ±SD
(standard deviation) as indicated. Statistical analysis was carried
out using GraphPad Prism 6 software (San Diego, CA, USA).
For multiple testing ANOVA followed by post hoc testing
(Bonferroni’s Multiple Comparison Test) was used. A p-value of
less than 0.05 was considered statistically significant (∗p < 0.05;
∗∗p< 0.01; ∗∗∗p< 0.001).
RESULTS
Domains Involved in TrkA/APP
Interaction
To identify APP region(s) that associates with TrkA, HEK293
cells were co-transfected with a TrkA full-length construct
plus a series of APP full-length and deletion constructs
(Figure 1A). Cell lysates immunoprecipitated with an anti-
TrkA antibody were analyzed by Western blot (WB) with
rabbit antibodies against N-terminal (NT) or C-terminal (CT)
of APP. We found that the APP juxtamembrane region
comprised between β and α secretase cleavage sites was
necessary for co-immunoprecipitation with TrkA as shown by
co-immunoprecipitation of APP-C99 and TrkA and lack of
co-immunoprecipitation of APP-C83 and TrkA (Figure 1B).
Similarly, by co-immunoprecipitation of APP with TrkA deletion
mutants (Figure 1C), we demonstrated that APP interacts
with a TrkA fragment which lacks 353 NT amino acids and
includes the intracellular and transmembrane domains (TrkA-
1-NT). Moreover, APP still interacts, albeit with reduced
efficiency, with TrkA-1CT lacking the intracellular CT 311
amino acids but including the extracellular and transmembrane
domains (Figure 1D). Taken together, these data suggests
that the transmembrane, the only one shared by TrkA-1-NT
and TrkA-1-CT, is important for interaction with APP and
that the intracellular (IC) domain of TrkA may contribute
to the binding to APP since its deletion decreases the
amount of co-immunoprecipitated APP. Moreover, the level of
immunoprecipitated proteins was similar in the absence and in
the presence of EDTA. This suggests that the formation of TrkA
APP complex does not require divalent cations, such as cupper
and zinc, known to influence APP oligomerization (Figure 1E).
FRET and BiFC Analysis of APP/TrkA
Interaction
To investigate the physical association of APP and TrkA FRET
was performed in HEK 293 cells transfected with TrkA-YFP
and APP-CFP plasmids. The average FRET efficiency values
measured was 8.1% ± 1.8 (Figure 2A). In a previous paper, the
FRET behavior of two tandem CFP-YFP fusion proteins has been
investigated (Karpova et al., 2003). A FRET efficiency value of
7.96% ± 0.38 was achieved for the CFP-YFP tandem proteins.
Comparison of our APP-YFP value with that of the CFP-YFP
tandem construct suggests that APP and TrKA are in close
proximity in the interacting complex.
Formation of APP/TrkA complexes and their subcellular
localization were further investigated by BiFC assay (Kerppola,
2006). We co-transfected HEK293 cells with an expression
vector encoding the aminoterminal fragment of venus fluorescent
protein (residues 1-173, VN) (Nagai et al., 2002) fused in frame
to the C-terminus of APP-695, hereon named APP-VN, with
vector encoding the C-terminus of TrkA fused in frame with
carboxyl fragment of venus fluorescent protein (residues 155-238,
VC), hereon named TrkA-VC. Negative and positive controls
consisted of transfection of TrkA-VC with ErbB3-VN, ErbB3
being a receptor for ligands of EGF family with no known
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FIGURE 1 | Identification of the APP and TrkA regions involved in APP/TrkA interaction. (A) Schematic diagram of APP constructs used in this study. All
constructs are derived from the human APP-695 isoform. This transmembrane glycoprotein consists of 695 amino acids and can be divided into an extracellular
region, a transmembrane domain (TMD) and a small intracellular domain (ID) the extracellular regions is divided into the E1 and E2 domains, linked by an acidic
domain. The domain E1 consists of a growth factor-like domain (GFLD) and the following copper-binding domain (CuBD). (B) Cell lysates of HEK293 cells,
transfected with the indicated plasmids, were immunoprecipitated with mab Trk (B3) or mab Bcl2 (C-2) (IgG) as control and probed with rabbit anti C-terminal (CT),
N-terminal (NT) APP antibodies and rabbit TrkA-CT (Abcam ab76291). Total protein extract (30 µg unbound) (INPUT) was also loaded as positive internal control of
electrophoretic mobility and immunoprecipitation efficiency. Each co-transfection has been performed at least three times with similar results. (C) Schematic diagram
of TrkA constructs used in this study. All constructs are derived from human TrkA. This receptor consists of 796 amino acids and can be divided in the extracellular
ligand-binding domain, [comprising leucine-rich motifs (LRR), two cysteine clusters (C1 and C2) and two immunoglobulin (Ig)-like domains], the TMD, and the
intracellular tyrosine kinase domain. (D) Cell lysates of HEK293 cells transfected with APP-695 and TrkA constructs were immunoprecipitated with mab 22C11 or
mab Bcl2 (C-2) (IgG) as control and then probed with rabbit anti-TrkA-CT (Abcam, ab76291) and TrkA-NT (H-190 (sc-14024). INPUT corresponds to 30 µg of total
unbound extract as in (B) ∗ and ∗∗ indicates the IgG heavy and light chains respectively. (E) Immunoprecipitation with anti-TrkB3 from lysate of HEK293 cells,
transfected with APP-695 and TrkA constructs, in the presence or absence of 5 mM EDTA. INPUT corresponds to 30 µg of total unbound extract as in (B). Arrow
and arrowhead indicate the partially glycosylated and fully glycosylated forms of TrkA, and the immature and mature forms of full length APP.
interaction with TrkA, and TrkA-VC with TrkA-VN known
to homodimerize (Shen and Maruyama, 2011) respectively
(Figure 2B). As reported in Supplementary Figure S1, APP
tagged with VN is expressed with the expected size and processed
normally.
As shown in Figure 2C, TrkA-VC and APP-VN reconstituted
a functional fluorophore indicating that they are in close
proximity. The strong BiFC signal indicates that TrkA/APP form
a complex, with a half-life that is longer than 50 min, the time
needed to produce a BiFC signal once the two halves bind to
each other (Hu and Kerppola, 2003 ). This result suggests that
the interaction did not result in the degradation of the TrkA/APP
complex. As expected, no fluorescence was observed in cells
expressing TrkA-VC/ErbB3-VN, TrkA-VN and APP-VN alone.
TrkA/APP complexes were observed not only in the plasma
membrane, but also inside the cells (Figures 2D,E). The level of
intracellular complexes was much higher than that in the plasma
membrane and exhibited distribution pattern within the cells
suggestive of an ER, and Golgi localization (see Supplementary
Figure S5).
To exclude that the observed interaction between APP and
TrkA proteins was due to their over-expression, we selected
cells expressing different levels of APP and TrkA (Figure 2D)
and found that cells with barely detectable levels of BiFC signal
(Figure 2D, c,d) exhibited a similar subcellular distribution
pattern as those having a strong BiFC signals (Figure 2D, a,b).
Interestingly, we detected BiFC also when TrkA-VC was
transfected with APP-VN bearing the Sw/In mutations
(Figure 2E), suggesting that mutations K596N, M597L and
V642F do not preclude APP binding to TrkA. Consistently,
co-immunoprecipitation confirmed that TrkA interacts with
APP-Sw/In (Figure 2F). By contrast, APP with the mutation
Y682G in the 682YENPTY687 domain, which is instrumental
for the association with TrkA (Matrone et al., 2011) was unable
to form BiFC signal (Figure 2E) and to immunoprecipitate
TrkA (Figure 2F). Of note, APP bound also the TrkA K538A
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FIGURE 2 | Visualization of TrkA-APP protein interaction using FRET and BiFC analysis. (A) Confocal microscope images of FRET acceptor photobleaching
assay of HEK293 cells co-transfected with APP-CFP and TrkA-YFP. The CFP and YFP images before and after YFP photobleaching, the merged image of CFP and
YFP prior to photobleaching, and pseudo-colored image showing an FRET efficiency values map. (B) The schematic diagram of dimerization pairs used in the BiFC
analysis. (C) HEK293 cells were transfected with TrkA-VN alone, TrkA-VC and ERB-VN, APP-VN alone, TrkA-VC and TrkA-VN, TrkA-VC and APP-VN. Fluorescence
images of HEK293 cells expressing the proteins indicated in each panel were acquired by confocal microscopy 18–24 h after transfection. (D) Four images of cells
transfected with TrkA-VC/APP-VN were selected to show cells with different level of protein expression (a, b: high level of expression; c, d: low level of expression)
but similar pattern of subcellular distribution; e, APP staining with mab 22C11 (red). (E) BiFC analysis shows that TrkA-VC interacts also with APP-Sw/In-VN but not
with APP-Y682G-VN, despite this latter is efficiently expressed when transfected (see immunostaining for APP performed with mab 22C11, red). (F) Cell lysates of
HEK293 co-transfected with TrkA and APP-Sw/In or APP-Y693G were immunoprecipitated with mab Trk (B3) antibody or mab Bcl2 (IgG) as control followed by
immunoblot with rabbit APP-N-terminal and rabbit TrkA.∗ and ∗∗ indicate the IgG heavy and light chains respectively.
mutant which is unable to autophosphorylate (Supplementary
Figure S2).
Quantification of BIFC Analysis
BiFC fluorescence intensity was quantified by FACS analysis
to determine the efficiency of fluorescence complementation
in cells transfected with the various form of APP and TrkA.
Mock transfected cells, as well as cells transfected with either
TrkA-VN, APP-VN or TrkA-VC produced no fluorescence
signal. Conversely, a peak of fluorescence was detected when
APP-VN and TrkA-VC were co-transfected, with a mean
value of 138.65 (arbitrary fluorescence units), similar to that
of positive control TrkA-VC/TrkA-VN (134.58) (Figure 3A).
The proportion of co-transfected cells showing BiFC signal
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FIGURE 3 | Quantification of BiFC by FACS analysis. (A) FACS analysis of HEK293 cells transfected with the indicated constructs. The M1 region was chosen
to best estimate the percentage of cells exhibiting BiFC signal in co-transfection of TrkA-VC and APP-VN. The percentage gated and total, mean and coefficient of
variation (CV) in each experiment are shown in the right panel. (B) The average of the percentage gated in (a) from three independent transfections. Error bars
represent SEM of the average of percentage gated (n = 3). (C) Half of the cells transfected for FACS analysis were collected, lysed and analyzed by Western blotting
with either rabbit anti-APP-NT and rabbit anti-TrkA-NT (H190) antibodies to ascertain equal transfection efficiency. Arrow and arrowhead indicate TrkA bands
corresponding to partially glycosylated and fully glycosylated forms, respectively. (D,E) Quantification by FACS analysis of HEK293 cells transfected with the TrkA-VC
plus the indicated APP mutant constructs, of the % BiFC positive cells and the mean fluorescence intensity (AU). Results are mean ± SEM of three independent
transfections performed in triplicate. ∗∗∗ < 0.0001; vs. TrkA-VC/APP-V. (F) Western blot analysis with either rabbit anti-APP-NT and APP-CT and rabbit anti TrkA
antibodies to ascertain equal transfection efficiency. (G) Visualization of BiFC signal (green) and TrkA (blue) and APP (red) immunostaining in HEK293 transfected with
TrkA-VC/APP-C99-VN but not in cells transfected with TrkA-VC/APP-C83-VN. Fluorescence images were acquired by confocal microscopy 18-24 h after
transfection. (H,I) Quantification by FACS analysis of HEK293 cells transfected with the APP-VN plus the indicated TrkA mutant constructs, of the % BiFC positive
cell and the mean fluorescence intensity (AU). Results are mean ± SEM of three independent transfections performed in triplicate. ∗ < 0.01; ∗∗∗ < 0.0001; vs.
TrkA-VC/APP-VN, One way Anova with Bonferroni post hoc test. (J) Western blot analysis either rabbit anti-TrkA-NT, TrkA-CT and rabbit anti APP antibodies to
ascertain equal transfection efficiency.
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was 25% ± 0.78 of BiFC positive cells for TrkA-VC/APP-
VN and a 23.35% ± 2.38 of BiFC positive cells for TrkA-
VC/TrkA-VN. These values were very close to that of control
cell transfected with plasmid coding full length YFP fused in
frame to C-terminus of APP-695 (APP-YFP) or C-terminus
of TrkA (TrkA-YFP) (27% ± 4 and 25.5 ± 5.3 respectively),
suggesting that the interaction occurs in all transfected
cells.
In cells co-transfected with TrkA-VC/APP-Y682G-VN
fluorescence intensity and % of BiFC positive cells were
indistinguishable from that of negative control cells transfected
with TrkA-VC/ErbB3-VN (Figure 3B). This finding is consistent
with fluorescence microscopy analysis, which revealed the lack of
BiFC signal for this mutant form of APP as well for the negative
control TrkA-VC/ErbB3-VN (Figure 2D). Cells transfected with
various constructs produced comparable amounts of protein
(Figure 3C).
Co-transfection of full length TrkA with APP deleted
constructs (Figure 1A) confirmed data obtained by
immunoprecipitation. Indeed, BiFC signal was produced
when TrkA-VC was co-transfected with APP-1-CT-VN, APP
s-α-VN or APP C99-VN vectors (Figures 3D,E,F). Interestingly,
no BiFC signal was evident for APP-C83-VN despite co-
transfected cells express efficiently TrkA and C83 proteins as
showed by WB and immunofluorescence analysis (Figures 3F,G).
Co-transfection of N or CT deleted TrkA-VC fusion constructs
with APP-VN produced BiFC signal. Moreover, we found that
354–488 TrkA fragment fused to VC was by itself capable of
generating a strong BiFC when co-transfected with APP 695-VN
(Figures 3H,I,J), suggesting that the transmembrane domain of
TrkA was sufficient for interaction with APP.
TrkA/APP Interaction Is Inhibited by
p75NTR, ShcC and Mint-2
Many proteins can be brought in proximity to each other by a
partner that functions as a scaffold for the assembly of a trimeric
protein complexes. Simultaneous binding by two proteins in the
vicinity of each other on the same scaffold results in increased
BiFC signal (Riese et al., 2013; Mo et al., 2014). We therefore
investigated whether the TrkA/APP interaction could be affected
by the co-expression of p75NTR, ShcC and Mint-2, well-known
TrkA and APP partners.
TrkA-VC and APP-VN were co-expressed with untagged
p75NTR in HEK393, and BiFC analysis was performed 24 h
later. There was no increase in BiFC efficiency, e.g., in the
number of BiFC positive cells or in the fluorescence intensity of
BiFC complex, the latter correlating with the size and stability
of the complexes (Riese et al., 2013; Mo et al., 2014). Indeed,
there were significant decreases in both of these parameters.
First, we measured a significant decrease in the fraction of
BiFC-positive cells, when compared with cells transfected solely
with TrkA-VC and APP-VN (8.96 ± 0.48 and 14.50 ± 05
respectively; p = 0.0001) (Figure 4A; Supplementary Figure S3).
Similarly, cells expressing p75NTR showed a significant decrease
in mean fluorescence intensity (51.7196 ± 4.8 and 115 ± 2.67
respectively; p = 0.0001) (Figure 4B). These data suggest that,
rather than promoting the interaction between APP and TrkA,
p75NTR actually opposes it, likely by sequestering APP or
TrkA (Figure 4C). Consistent with this observation, we found
that APP-VN and TrkA-VC also form complexes in cells,
such as NIH-3T3 and HeLa, which do not express p75NTR
(Figures 4C,D).
We also evaluated the possible contribution of the
neurospecific adapator protein ShcC in mediating TrkA/APP
interaction. This adaptor protein was reported to contact
the phosphotyrosine motif of TrkA and APP through its
NT PTB domain (Dikic et al., 1995; Tarr et al., 2002b) and
possibly the phosphotyrosine motif of APP through its
C-terminal Src-homology2(SH2) domain (Tamayev et al.,
2009). ShcC transfection, reduced the BiFC signal generated
from co-expression of TrkA-VC/APP-VN of about 60% [(BiFC
positive cells: 5.37± 0.8 and 14.50± 05 respectively; p= 0.0001;
fluorescence intensity: 50.70± 11.94 and 115± 2.67; p= 0.0001)]
(Figures 4A,B; Supplementary Figure S3) supporting that ShcC,
like p75NTR, prevents instead of promoting TrkA and APP
interaction.
Finally, a similar effect of Mint-2 in antagonizing TrkA/APP
interaction was observed. This neural adaptor protein, involved
in synaptic vesicle docking and exocytosis, is able to contact
TrkA (Zhang et al., 2009) as well as APP (Biederer et al.,
2002). Its expression resulted in a decrease by ∼30% of
fluorescence intensity compared to control cells (73 ± 8.1 and
115 ± 2.67 respectively, p = 0.01), with a slight decrease in
the number of BiFC positive cells (11.3 ± 1 and 14.50 ± 05
respectively) (Figures 4A,B; Supplementary Figure S3). The lack
of involvement of ShcC and Mint-2 in promoting TrkA/APP
complex formation is in accord with the co-immunoprecipitation
of TrkA with APP-1-CT which lacks the motif1Y682ENPTY687
necessary for interaction with the PTB motif of ShcC and Mint-2
(Figure 1B).
Notably, the extent of TrkA-VC and APP-VN expression was
not decreased by co-transfection of p75NTR, ShcC or Mint-
2, as shown by WB analysis (Figure 4E), indicating that the
reduced BiFC signal is not due to a variations in expression level
of proteins in the different conditions. Moreover, cell viability
was not affected in any of the transfection indicating no overt
cytotoxicity of the ectopically expressed proteins (Figure 4F).
Although our data demonstrated that neither p75NTR nor
ShcC nor Mint-2 is required for promoting association between
APP and TrkA, other factors such as sortilin (Vaegter et al., 2011;
Gustafsen et al., 2013) might be involved. Alternatively, APP and
TrkA might interact directly.
Visualization of TrkA/APP Complex
In situ by Proximity Ligation Assay in
Septal Primary Neurons
We next used PLA assay to detect interaction between
endogenous TrkA and APP in primary cultures of rat septal
neurons. Preliminary confocal fluorescence microscopy analysis
confirmed a strong colocalization of the signal for the two
proteins (Figure 5A; Triaca et al., 2016). Next, we used a panel
of anti TrkA and anti APP antibodies in PLA assay.
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FIGURE 4 | TrkA/APP interaction is inhibited by low-affinity NGF receptor p75, ShcC and Mint-2. (A,B) Quantification by FACS analysis of HEK293 cells
transfected with the indicated constructs of the % BiFC positive cell and the mean fluorescence intensity. Results are mean ± SEM of three independent
transfections performed in triplicate. ∗∗∗ < 0.0001; compared to TrkA-VC/APP-VN, One way Anova with Bonferroni post hoc test. (C) Western blot analysis showing
expression of p75NTR in cell lines indicated. (D) Visualization of TrkA/APP interaction by BiFC analysis in HEK293, NIH-3T3 and HeLa transfected with the indicated
plasmids. Fluorescence images were acquired by confocal microscopy 18–24 h after transfection. (E) Half of the cells transfected for FACS analysis were collected,
lysed and analyzed by Western blotting with either rabbit anti APP-NT (A8967, Sigma Aldrich), rabbit anti TrkA-NT (H190), rabbit anti p75 NTR polyclonal antibody (N
3908, Sigma Aldrich), mouse anti ShcC, rabbit anti-Mint2 (sc-30135, X11β M-220 Santa Cruz Biotecnology). (F) Cell viability determined by the MTT assay 24 h after
transfection. Results are the means (±SEM) of duplicate determinations from three independent experiments and are reported as percentage of mock transfected
cells.
A strong signal in a form of spots reflecting TrkA-APP
interaction, was detected with different specific antibodies against
CT of TrkA and APP (Figure 5B). No or faint signal was
observed with antibodies against the NT of TrkA and APP
despite these antibodies are useful for staining APP and TrkA in
immunofluorescence experiments (Supplementary Figure S4B).
This finding suggests that TrkA and APP are spatially oriented in
a manner that the distance between their NTs is greater than the
one required generating a PLA signal. As control, no signal was
detected by omission of one of the primary antibodies or use of
an unrelated antibody (Supplementary Figure S4A).
Strong PLA signals were observed throughout the entire
neuron, from the cell body to the distal parts of the neurites
(Figure 5B), the majority of PLA signal being restricted, as
expected, to cholinergic (choline acetyltransferase, Chat positive)
neurons (Figure 5C). Trk B3 antibody is a pan Trk antibody
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FIGURE 5 | TrkA and APP interaction in septal primary neurons measured by proximity ligation assay. (A) Confocal microscopy analysis of double-staining
of APP (rabbit APP-CT A8717, red) and Trk (mouse Trk B3, green) in primary septal neurons showing co-localization of APP and TrkA. (B) The TrkA/APP complex
was visualized by PLA, which generates red dots when the two proteins are in close proximity. Mouse and rabbit anti TrkA-CT (mouse Trk B3 and rabbit TrkA
ab7261) and anti APP-CT (rabbit APP-CT A8717 and mouse APP clone C1-6.1) were used as primary antibodies and anti-mouse MINUS and anti-rabbit PLUS were
used as secondary antibodies. Red fluorescent dot represents single interaction between TrkA and APP. (C) In addition to PLA (red dots), rat primary septal neurons
were immunostained with goat anti ChAt (green) and with DAPI for nuclei (blue). (D) PLA assay using mouse anti APP (C1-6.1) and rabbit anti TrkB (sc-119) or TrkC
(sc-117).
which does not distinguish between TrkA, TrkB and TrkC
receptors. To assess the contribution of hypothetical TrkB/APP
and TrkC/APP complexes to the signal observed by PLA, we
repeated the assay with rabbit anti-TrkB-specific (Sc-13) or anti-
TrkC-specific (Sc-798) and mouse anti-APP-CT (clone C1/6.1)
antibodies. Few scattered PLA dots were detected in both
conditions (Figure 5D) suggesting that APP might form complex
also with TrkB and TrkC, which are both expressed, although to a
lower level than TrkA, in cholinergic neurons (Salehi et al., 1996;
Mufson et al., 2002).
TrkA/APP Complex Is Modulated by NGF
and Cellular Trafficking Perturbations
Proximity ligation assay signals were prominent in the
perinuclear region and along neuronal processes of
primary neurons (Figures 5C and 6A). By combining
immunofluorescence with PLA assay, we found that PLA
signal colocalizes with GM130 (r = 0.49 ± 0.18), a cis Golgi
matrix protein, and with calnexin (r= 0.068± 0.049), an integral
ER protein) (Figure 6B). Consistent with such a localization
in ER and Golgi, APP/TrkA complexes in transfected HEK293
cells were shown to colocalize with ER and Golgi markers
(mCherry ER-3 and tomato-mannosidase II protein respectively)
as well as with marker of early endosome (Ds-red rab5)
and recycling endosome (Ds-red rab-11) (Supplementary
Figure S5).
Treatment with NGF (100 ng/ml for 1 h) increases the number
of PLA dots by∼50% compared to untreated cells (Figures 6A,B)
thus confirming that NGF favors the interaction between TrkA
and APP (Triaca et al., 2016). This increase occurred also in
GM130 positive structures (Figure 6C) where the number of PLA
dots colocalizing with GM130 was highly significantly increased
in NGF treated cells compared to untreated cells (11724 ± 1478
and 6230 ± 1234 respectively; ∗p = 0.019 t-test). A similarly
strong increase was observed in the number of PLA dots
colocalazing with calnexin in NGF treated cells (14430 ± 2249
vs. 4602 ± 1302; p = 0.0316 t-test) (Figure 6C). Notably, the
increased PLA signal under NGF treatment was not due to
increased APP or TrkA levels (data not shown) as previously
reported Triaca et al. (2016).
To confirm the colocalization of PLA signal with ER/Golgi,
we performed PLA assay after application of brefeldin A
(BFA, 5 µg/ml for 3 h) a macrocyclic lactone antibiotic that
induces redistribution of Golgi proteins into the ER and blocks
anterograde transport (Pelham, 1991). Indeed, in BFA treated
neurons APP and TrkA co-localized in the entire cell body and
the initial segment of neurites, being absent in the distal part
of neurites. Accordingly, the PLA signal was intense throughout
the entire cell body and the initial segment of the neurites
(Figure 6D).
The overall effect of BFA on TrkA/APP interaction was further
determined by counting the number of dots per cell. Under
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FIGURE 6 | Modulation of APP/TrkA association by NGF and trafficking perturbation. (A) Representative images of PLA performed with APP-CT and Trk B3,
antibodies showing the interaction of APP and TrkA in primary septal cultures (12 DIV) untreated (Ctrl) or treated with NGF (100 ng/ml for 1 h). Positive signal of
interaction is shown as red dot, nuclei are stained with DAPI. (B) Quantification of the PLA signal in primary neurons untreated and treated with NGF (100 ng/ml for
1 h)). The graph represents quantitative analysis of the number of PLA fluorescent red puncta/cell counted in five different fields and for a total of 20–30 cells
examined and are expressed as mean ± SEM ∗∗p < 0.01 Student t-test. (C) Co-localization of PLA signal with GM130 and calnexin in untreated and NGF treated
cells. A representative z-stack of images was collected from each cell. (D) Confocal microscopy images of immunofluorescence and PLA signal [both performed with
anti-APP-CT (red) and anti-Trk B3 (green) antibodies], of untreated (Ctrl) and BFA (5 µg/ml for 3 h), cytochalasin D (5 µM for 3 h) and colchicine (100 µM for 3 h)
treated primary septal cultures (12 DIV) are shown. PLA dots in cytocalasin D treated cells are distributed in cell body and also along the neuritis coherently with the
co-localization signal detected by immunofluorescence. Nuclei are stained with DAPI (blue). (E) Quantification of the PLA signal of APP/TrkA interaction in primary
neurons untreated (Ctrl) and treated with BFA, cytochalasin D and colchicine. A total of 20–30 cells were examined. ∗∗∗p < 0.001 when compared to Ctrl. Student
t-test was used for statistical analysis. (F) Representative Western blot analysis with anti APP-CT (A8717, Sigma Aldrich), anti TrkA-CT (Abcam, ab76291) antibodies
and anti β-actin as loading control under treatments indicated.
BFA treatment the number of complexes increased by 3.5 fold
compared to untreated cells (Figure 6E).
Similar results were obtained by disrupting microtubule-
dependent anterograde and retrograde transport of vesicles
(Cid-Arregui et al., 1995; Bloom and Goldstein, 1998) within the
neurites with the use of colchicine (100 µM for 3 h) (LeBlanc and
Goodyer, 1999) and by perturbing the actin cytoskeleton and the
endocytic pathway with cytochalasin D (5 µM for 3 h) (Fujimoto
et al., 2000) (Figures 6D,E). Quantification of PLA dots showed
that colchicine treatment increased by twofold the number of
interaction events. At the dose used, BFA, cytochalasin D and
colchicine had no effect on APP and TrkA levels (Figure 6F)
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and on cell survival (data not shown). Overall, these experiments
confirm the specificity of TrkA/APP localization at Golgi and ER
sites.
Decrease of TrkA/APP Complex during
Cell Death
We have recently demonstrated that the amount of TrkA bound
to APP is reduced in AD brains (Triaca et al., 2016). Since
neuronal loss is a pathological feature of AD, we investigated
the fate of TrkA/APP complex in different paradigm of cell
death. Aβ-peptide has been reported to induce apoptosis on
cultured primary neurons (Shaked et al., 2006). We found that
TrkA/APP interaction was dramatically reduced 12 h following
exposure to 20 µM Aβ-peptide 1–40 (22 ± 9% compared to Ctrl
untreated cells: ∗∗p = 0.005 t-test) (Figures 7A,B). Importantly,
this decrease in APP/TrkA complexes was apparent before overt
signs of cell death. Indeed, viability detected by MTT assay
and intact nuclei count was not significantly different between
treated and untreated cultured cells (Supplementary Figure S6)
and the active caspase-3 was slightly increased in Aβ-treated cells
compared to control (Figure 7C), showing that disruption of
TrkA/APP complexes precedes Aβ-peptide mediated cell death.
Dispersal of TrkA/APP interaction was also observed with more
aggressive and toxic Aβ-peptide 1–42 and 25–35 (Supplementary
Figure S7). Similarly, we found that other pro-death agents such
staurosporine (30 nM) which induces apoptosis with caspase-3
activation (Figure 7C) and rapamycin (10 nM), which causes
autophagy (Figure 7D) induced a disruption of TrkA/APP
complexes observable within 6 h (PLA dots/cell: 51 ± 6
and 57 ± 8 respectively compared to Ctrl untreated cells)
(Figures 7A,B) when viability was not significantly affected
(Supplementary Figure S6).
Notably, we found that the staining level for APP and TrkA
was similar in Ctrl, staurosporine and rapamycin treated cells
suggesting that the decrease of TrkA/APP complex is not caused
by their degradation (Figures 7E,F). Moreover, no decrease in the
level APP or TrkA were observed by WB under staurosporine and
rapamycin treatments (Figure 7G)
Interestingly, we found that loss of TrkA/APP interaction
was accompanied with an increased production of β-CTF
APP fragment (Figures 7G,H). These data demonstrate that
TrkA/APP complexes are sensitive to cell death stimuli associated
with amyloidogenic APP processing, which also occurs following
NGF deprivation (Matrone et al., 2008).
DISCUSSION
Formation of TrkA/APP complexes is correlated with the
physiology and pathophysiology of APP processing and
transcriptional activity (Tarr et al., 2002a; Zhang et al., 2014;
Triaca et al., 2016) and NGF-TrkA signaling (Matrone et al.,
2011; Zhang et al., 2013). However, no evidence of a close
proximity of the two proteins has been documented prior
to this work. Resolving this issue is relevant to resolving the
physiological and pathological roles of APP, a duality that
hinges in CBFN on the supply of NGF. Therefore, we used
co-immunoprecipitation, BiFC and PLA to get detailed insight
into the formation of TrkA/APP complexes. In the field of
neurodegenerative diseases, BiFC and PLA have frequently been
used to study protein-protein interactions in Alzheimer’s and
Parkinson’s disease (Chen et al., 2006; Waldron et al., 2008;
Gonçalves et al., 2010; Isbert et al., 2011; Weyer et al., 2011;
Teranishi et al., 2012; Gu et al., 2013; Riese et al., 2013; Lundgren
et al., 2015; Roberts et al., 2015). Both BiFC and PLA can be used
to test whether two proteins are in close proximity, although do
not specify if they bind directly or if their interaction is mediated
by a common partner.
By co-immunoprecipitating TrkA with APP deletion mutants,
we identified APP residues 597–612 as essential for binding to
TrkA (Figure 1B and see also Zhang et al., 2014), which we
confirmed by BiFC assay (Figures 3D,E,G). Additionally,
we showed that TMD/intracellular domains of TrkA are
involved in the interaction with APP (Figure 1D), and that the
region of TrkA residues 354–488 is sufficient for binding with
APP (Figures 3H,I). Taken together these data point to the
transmembrane/juxtamembrane domains of TrkA and APP as
crucial for TrkA/APP complex formation. Interestingly, previous
studies (Fombonne et al., 2009) demonstrated that the same
residues in APP (597–612) are also important for binding to
p75NTR. This short stretch of amino acids contains the α and
β secretase recognition sites and is therefore essential for the
production of either physiologically relevant APP processed
forms or toxic fragments such as Aβ peptides and β-CTF. We
therefore suggest that competition between p75NTR and TrkA
for association with APP through this short stretch of amino
acids in APP may underlie the inhibition of TrkA/APP complex
formation by p75NTR. In addition, competition for binding to
the same surface may explain the functional antagonism of the
two NGF receptors, with p75NTR promoting and TrkA reducing
the formation of Aβ peptides and β-CTF (Rossner et al., 1998;
Fombonne et al., 2009; Zhang et al., 2014; Triaca et al., 2016). By
the same reasoning, it is tempting to speculate that TrkA binding
also reduces formation of APP homodimers, an interaction that
requires the APP transmembrane domain and correlates with
amyloidogenic processing of APP. Interestingly, we showed
that NGF, which protects neurons from cell death and the
amyloidogenic processing of APP, also increases TrkA/APP
association (Figure 6A). Importantly, APP homodimer
formation has many physiological functions. For instance,
homodimerization involving the APP ectodomain supports
the role of APP in neuronal migration during embryogenesis
(Young-Pearse et al., 2007) and homodimerization involving the
APP transmembrane domain is important for APP processing by
β and γ secretases (Scheuermann et al., 2001).
We have also shown that p75NTR, Mint2 and ShcC, three
partners of both APP and TrkA, reduce rather than favor
TrkA/APP complex formation (Figures 4A,B). It would be
important to assess whether p75NTR, Mint2 or ShcC contribute
to regulating APP homodimerization.
The TrkA/APP complexes were found in the ER, Golgi,
cell surface and endocytic vesicles. This distribution, shown by
co-localization with compartment-specific markers (Figures 2C
and 6C; Supplementary Figure S5) was confirmed by treatment
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FIGURE 7 | Reduction of PLA signal during cell death. (A) Representative PLA assay performed with APP-CT and Trk B3 antibodies in primary septal cultures
(12 DIV) untreated (Ctrl) or treated with Aβ 1–40 (20 µM), staurosporine (30 nM) and rapamycin (10 nM) for 6 h. (B) The graph represents quantitative analysis of the
number of PLA fluorescent red puncta/cell counted in five different fields and for a total of 20–30 cells examined and are expressed as mean ± SEM (∗∗p < 0.005,
Student t-test was used for statistical analysis). (C) Western blot analysis for cleaved and active capsase-3, is reported for Ctrl, Aβ 1–40 and staurosporine treated
cells for 12 h. (D) Representative blot for LC3 in Ctrl and rapamycin treated cells for 12 h. Post-translational modification of cytosolic LC3-I (Light Chain 3 of
Microtubule Associated Protein 1A/B) to LC3-II is a useful index of autophagy. (E) APP and TrkA expression in Ctrl and staurosporine and rapamycin treated cells.
Double immunofluorescence for APP (red) or TrkA (green) and DNA (DAPI, blue) in Ctrl condition and following the indicated treatments for 12 h. (F) Bar plot
summarizes the APP and TrkA mean fluorescence intensity in Ctrl and treated cultures. Fluorescence intensity is reported in arbitrary unit (AU). No significant
difference were observed between Ctrl condition and following staurosporine or rapamycin exposure. (G) Representative Western blot of TrkA, APP and β-CTF in
neurons treated with staurosporine (30 nM) and rapamycin (10 nM) for 12 h. (H) Graph depicting quantification of immunoreactivity for TrkA, APP and β-CTF bands
normalized to β-actin (used as loading control) in neurons treated with staurosporine and rapamycin for 12 h (∗p < 0.05; ∗∗∗p < 0.0001). Results are the means
(±SEM) of duplicate determinations from three independent experiments and are reported as percentage of Ctrl cells.
with drugs that perturb cellular trafficking (Figure 6D) and is
consistent with the known physiological trafficking of APP and
TrkA (Haass et al., 2012; Goh and Sorkin, 2013; Farina et al.,
2015). Both APP and TrkA form homodimers in the ER/Golgi
before reaching the cell surface (Khalifa et al., 2010; Shen and
Maruyama, 2011; Farina et al., 2015).
TrkA spontaneously dimerizes in the ER before reaching
the cell surface, where it has full accessibility to NGF. NGF
binding induces the rotation of the transmembrane domains of
the preformed receptor dimers, resulting in rearrangement of
the cytoplasmic domains for activation and transmission
of NGF-mediated signaling cascades (Shen and Maruyama,
2011). Thus, it is likely that the known effect of APP in
regulating the NGF/TrkA signaling pathway (Matrone et al.,
14; Shen and Maruyama, 2011; Zhang et al., 2013) might
require a fine regulation of balance between TrkA dimer and
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TrkA/APP complexes. Importantly, NGF increases the number
of TrkA/APP complexes in every compartment, including the
ER and Golgi apparatus, as measured by PLA on rat primary
septal neurons (Figures 7B,C). This increase in TrkA/APP
complexes did not depend on augmented levels of TrkA and
APP, and occurred within 1 h of treatment with NGF. Although
we do not yet know the signaling pathway that is responsible
for this effect, a possible explanation may come from some
of our recent findings. In particular, phosphorylation of APP
Thr668 prevents the interaction between TrkA and APP, and
NGF stimulation decreases APP phosphorylation in Thr668, via
inhibition of c-Jun N-terminal protein kinase (JNK) (Triaca et al.,
2016).
We observed that TrkA/APP complexes decrease in
number, without apparent TrkA or APP degradation, as
an early response to cell death stimuli such as Aβ peptide,
staurosporine or rapamycin. Dissociation of TrkA/APP
complexes is clearly observable before loss of cell viability
(Figure 7A; Supplementary Figure S6). Although the cascade
of events that lead to cell death upon these treatments
may differ, it is intriguing that both Aβ and staurosporine
rely on increased APP/APP dimer formation, which leads
to increased production of Aβ peptide via a positive
feedback mechanism. In fact, APP/Aβ-peptide binding induces
APP homodimerization, which may, in turn, influence Aβ
production (Scheuermann et al., 2001; Shaked et al., 2006;
Munter et al., 2007; So et al., 2012). On the other hand,
staurosporine-induced cell death, which is characterized by
amyloidogenic APP processing (Sodhi et al., 2008) could be
due to the up-regulation of APP phosphorylation at T668
(Sodhi et al., 2008). If we assume that TrkA bound to
APP prevents APP homodimerization, the dissociation of
TrkA/APP complexes would be an early event necessary to
allow formation of APP/APP complexes. Further studies are
necessary to assess the interplay and the relevance of these
phenomena.
Overall, our finding that a 16 amino acid stretch of APP
contains the determinants not only for its physiological as well
as pathological processing, but also for their modulation by
the TrkA receptor, focuses new attention on the interactions
between APP and TrkA and the possibilities for modulating
their reciprocal interplay. This is especially true given the known
importance of TrkA in translating crucial messages during
development and in the adult brain.
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